Search clinical trials for: Urine Growth Factors

Total 88806 results

National Cancer Institute (NCI)

Not yet recruiting

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

Recurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Fallopian Tube Undifferentiated Carcinoma | Recurrent Ovarian Clear Cell Adenocarcinoma | Recurrent Ovarian Undifferentiated Carcinoma and other conditions
Erasmus Medical Center
ZonMw: The Netherlands Organisation for Health Research and Development; AI...

Not yet recruiting

Optimizing Reversal of HIV Latency With Combination Therapy (ORBIT)

Hiv

Netherlands
Bio-Thera Solutions

Not yet recruiting

BAT1308 Combined With Platinum-Based Chemotherapy± Bevacizumab For PDL1-Positive (CPS ≥1) Cervical Cancer

Cervical Cancer

China
Saint Thomas Hospital, Panama

Not yet recruiting

Angiogenic Factors in the Conservative Management of Gestational Hypertension

Gestational Hypertension
M.D. Anderson Cancer Center

Recruiting

Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

Ovarian Cancer

United States
National Nutrition and Food Technology Institute
Shahid Beheshti University of Medical Sciences

Recruiting

Effect of Quercetin Supplementation on Endometriosis Outcomes

Endometriosis

Iran, Islamic Republic of
First Affiliated Hospital of Zhejiang University

Recruiting

Immunomodulators on HIV-1 Reservoir

HIV Infections

China
The First Affiliated Hospital of Soochow University

Not yet recruiting

Efficacy and Safety of Daratumumab in Combination With Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma

Newly Diagnosed Multiple Myeloma
General Hospital of Ningxia Medical University

Not yet recruiting

The Effect of Intravenous Lidocaine on THBS2 and Angiogenic Factors Expression in Women Undergoing Cervical Cancer Surgery

Cervical Cancer | Metastatic Cancer
AstraZeneca
Daiichi Sankyo

Recruiting

Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Gastric Cancer | Colorectal Cancer | Ovarian Cancer | Endometrial Cancer | Urothelial Cancer | Biliary Tract Cancer | Metastatic Castration-resistant Prostate Cancer

Spain, China, Korea, Republic of, Canada, Italy, Poland, Turkey, United Kingdom, Japan, Taiwan, United States, France, Germany, Switzerland
ImmunoGen, Inc.
GOG Foundation

Recruiting

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA)

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States, Korea, Republic of, Spain, Australia, Canada, United Kingdom, Italy, Czechia, Philippines, Israel, Belgium
National Cancer Institute (NCI)

Recruiting

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

Burkitt Lymphoma | Plasmablastic Lymphoma | Non-Hodgkin Lymphoma | Diffuse Large Cell Lymphoma | B-Cell Neoplasm

United States
Fundación Eduardo Anitua

Not yet recruiting

Plasma Rich in Growth Factors (PRGF) for the Treatment of Lichen Sclerosus Atrophicus of the Vulva (PRGF)

Lichen Sclerosus of Vulva
Hellenic Society of Hematology
Sanofi

Not yet recruiting

A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor

Neoplasms | Neoplasms by Histologic Type | Hematologic Diseases | Multiple Myeloma | Neoplasms, Plasma Cell | Paraproteinemias | Blood Protein Disorders | Renal Impairment

Greece
Hospital Universitari Vall d'Hebron Research Institute
Instituto de Salud Carlos III; Roche Diagnostics GmbH

Not yet recruiting

Management of Early-onset Fetal Growth Restriction: Angiogenic Factors Versus Feto-placental Doppler (earlyGRAFD)

Placenta Diseases | Fetal Growth Retardation | Preeclampsia

Spain
Roswell Park Cancer Institute
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; Celldex Therapeutics

Recruiting

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Serous Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Platinum-Sensitive Ovarian Carcinoma | Recurrent Fallopian... and other conditions

United States
Hellenic Society of Hematology
Sanofi

Not yet recruiting

A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment

Neoplasms | Neoplasms by Histologic Type | Hematologic Diseases | Multiple Myeloma | Neoplasms, Plasma Cell | Paraproteinemias | Blood Protein Disorders | Renal Impairment

Greece
M.D. Anderson Cancer Center
Lyvgen Biopharma Holdings Limited

Recruiting

Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors

Gastric Cancer | Metastatic Uveal Melanoma | Metastatic Head and Neck Carcinoma | Metastatic Hepatocellular Carcinoma | Metastatic Ovarian Carcinoma | Metastatic Soft Tissue Sarcoma | Metastatic Esophageal | Metastatic HPV Related Solid Tumors

United States
M.D. Anderson Cancer Center

Recruiting

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Chondrosarcoma | Advanced Malignant Solid Neoplasm | Stage III Uterine Corpus Cancer AJCC v8 | Stage IV Uterine Corpus Cancer AJCC v8 | Stage IVA Uterine Corpus Cancer AJCC v8 | Stage IVB Uterine Corpus Cancer AJCC v8 | Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous... and other conditions

United States
Merck Sharp & Dohme LLC

Recruiting

MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)

Uterine Cervical Neoplasms | Stomach Neoplasms | Urinary Bladder Neoplasms | Hepatocellular Carcinoma | Esophageal Neoplasms | Ovarian Neoplasms | Endometrial Neoplasms | Squamous Cell Carcinoma of Head and Neck | Cholangiocarcinoma | Triple Negative Breast Neoplasms | Gallbladder Neoplasms

United States, Chile, Colombia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, Poland, Spain, Taiwan, Turkey, Canada
National Cancer Institute (NCI)

Recruiting

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Papillary Renal Cell Carcinoma | Hereditary Leiomyomatosis and Renal Cell Carcinoma | Sporadic Papillary Renal Cell Carcinoma

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Recruiting

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Serous Adenocarcinoma and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV

Kaposi Sarcoma | Viral Associated Malignancies | EBV/KSHV-associated Lymphomas

United States
Peking University Third Hospital

Recruiting

Cohort Construction for Preterm Infants With Growth Retardation and Its Influencing Factors

Problem With Growth of an Infant

China
Calico Life Sciences LLC
AbbVie

Recruiting

A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors

Advanced Solid Tumor Cancer

United States, Korea, Republic of, Spain, Israel, Japan, France
Fundació Institut de Recerca de l'Hospital de la...
Fundacion Clinic per a la Recerca Biomédica

Recruiting

sFlt1/PlGF and Planned Delivery to Prevent Preeclampsia at Term. (PE37)

Preeclampsia | Intrauterine Growth Restriction | Perinatal Death | Maternal Hypertension | Neonatal Outcome

Spain, Belgium, Czechia, Poland, India
Fondazione Policlinico Universitario Agostino Gemelli...
GlaxoSmithKline

Recruiting

Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment (NItCHE-MITO33)

Ovarian Cancer

Italy
Aarhus University Hospital
Rigshospitalet, Denmark; Herlev Hospital

Recruiting

TDM for Optimized Outcome in Patients With mRCC.

Kidney Cancer | Renal Cell Carcinoma Metastatic | Drug Toxicity | Drug Side Effect | Drug Mechanism

Denmark
Alliance Foundation Trials, LLC.
Eli Lilly and Company; Pfizer; Genentech, Inc.; Foundation Medicine

Recruiting

A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer (EndoMAP)

Endometrial Cancer

United States
Emory University
National Cancer Institute (NCI); Janssen Scientific Affairs, LLC

Recruiting

Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure

Renal Failure | Plasma Cell Myeloma

United States
Duke University
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Recruiting

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) (POPS or POP02)

Heart Failure | Pain | Pneumonia | Hypertension | Edema | Hemophilia | Insomnia | Pulmonary Arterial Hypertension | Coagulation Disorder | Asthma in Children | Down Syndrome | Attention Deficit Hyperactivity Disorder | Bronchopulmonary Dysplasia | Hypokalemia | Hyperphosphatemia | Primary Hyperaldosteronism | Adrenal Insufficiency and other conditions

United States, Canada
Immunocore Ltd

Recruiting

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Select Advanced Solid Tumors

United States, Belgium, Korea, Republic of, Australia, Germany, United Kingdom, Spain, Poland, Austria, Brazil, Canada, New Zealand, France, Italy, Netherlands, Switzerland
Bristol-Myers Squibb
Novartis; Clovis Oncology, Inc.; Janssen Pharmaceuticals; Exelixis

Recruiting

Pan Tumor Rollover Study

Cancer

United States, Israel, Spain, Italy, Germany, Australia, Belgium, China, Korea, Republic of, Greece, Japan, Argentina, Austria, Brazil, Canada, Chile, Denmark, Finland, France, Hungary, Ireland, Mexico, Netherlands, Poland, Russian Federation and more
Toray Industries, Inc

Recruiting

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Melanoma | Renal Cell Carcinoma | Gastric Cancer | Colorectal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Solid Tumor | Cholangiocarcinoma | Bladder Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Cancer | Palpable Subcutaneous Malignant Lesions

United States, France
University Hospital, Grenoble

Recruiting

Evaluation of a Promising New Combination of Protein Kinase Inhibitors on Organotypic Cultures of Human Renal Tumors (COMBOREIN)

Kidney Cancer

France
Celgene

Recruiting

Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)

Lymphoma

Japan
University Hospital, Montpellier

Recruiting

Evaluation of Cardiovascular Risk Factors in Incident Dialysis Patients

Chronic Kidney Disease

France
University Hospital, Montpellier

Recruiting

New Biomarkers of Bone Mineral Metabolism as Cardiovascular Risk Factors in Chronic Kidney Disease Patients

Chronic Kidney Disease

France
Novartis Pharmaceuticals

Active, not recruiting

Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

Renal Cell Carcinoma | Colorectal Cancer | Gastroesophageal Cancer

United Kingdom, Australia, Belgium, Germany, Italy, Taiwan, Czechia, Israel, Spain, Japan, Singapore, Canada, Korea, Republic of, United States, Chile
Eisai Inc.
Merck Sharp & Dohme LLC

Active, not recruiting

Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma (CLEAR)

Renal Cell Carcinoma

Korea, Republic of, Spain, United States, Netherlands, Ireland, Canada, United Kingdom, Poland, Italy, Australia, Russian Federation, Belgium, Israel, France, Greece, Czechia, Switzerland, Austria, Germany, Japan
ImmunoGen, Inc.

Completed

Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Cancer

United States, Spain, Belgium, Canada
Hoffmann-La Roche
GOG Foundation; European Network of Gynaecological Oncological Trial Groups...

Active, not recruiting

A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors (BOUQUET)

Ovarian Cancer

United States, Korea, Republic of, France, Germany, Spain, Italy, Canada, Russian Federation, United Kingdom, Turkey, Australia, Czechia, Switzerland
National Cancer Institute (NCI)

Active, not recruiting

Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma

Kaposi Sarcoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Glioma | Hematopoietic and Lymphoid Cell Neoplasm | Melanoma | Lymphoma | Multiple Myeloma | Recurrent Ovarian Carcinoma | Breast Carcinoma | Recurrent Head and Neck Carcinoma | Recurrent Lung Carcinoma | Recurrent Skin Carcinoma | Gastric Carcinoma | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory... and other conditions

United States, Puerto Rico, Guam
National Cancer Institute (NCI)

Active, not recruiting

Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer

Sarcoma | Metastatic Renal Cell Carcinoma | Metastatic Melanoma | Recurrent Renal Cell Carcinoma | Recurrent Melanoma | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Malignant Solid Neoplasm | Metastatic Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Clinical Stage IV Cutaneous Melanoma... and other conditions

United States, Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery

Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v7 | Metastatic Kidney Carcinoma

United States
AbbVie
Roche-Genentech

Active, not recruiting

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

Multiple Myeloma

United States, Australia, Canada, China, Czechia, Denmark, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Russian Federation, Singapore, Spain, Sweden, Turkey, Ukraine, United Kingdom
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Mucinous Adenocarcinoma and other conditions

United States, Korea, Republic of, Canada
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Stage IA Fallopian Tube Cancer AJCC v6 and v7 | Stage IA Ovarian Cancer AJCC v6 and v7 | Stage IB Fallopian Tube Cancer AJCC v6 and v7 | Stage IB Ovarian Cancer AJCC v6 and v7 | Stage IC Fallopian Tube Cancer AJCC v6 and v7 | Stage... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Endometrioid Adenocarcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Ovarian High Grade Serous Adenocarcinoma | Platinum-Resistant... and other conditions

United States, Canada

Search clinical trials for: Urine Growth Factors

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Costa Rica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations